In Science this week: fruit fly mothers pass on epigenetic information, and more.
Based on a 537-patient validation study, the markers appear capable of detecting early-stage disease and could be useful for monitoring high-risk populations.
Asia Genomics will make CellMax's tests, including the CellMax-DNA Genetic Cancer Risk Test Assure and the CellMax-CRC Protect Test, available immediately.
In PNAS this week: analytical method for assessing shared variants, treatment targets in hereditary pancreatic cancer, and more.
Through prospective pancreatic ductal adenocarcinoma testing, researchers saw germline mutations in new genes and in cases outside of current germline testing criteria.
Philips has teamed with Illumina and Intermountain Healthcare's Navican on informatics for precision medicine and signed a genome analytics deal with Memorial Sloan Kettering Cancer Center.
In Science this week: new test for pancreatic ductal adenocarcinoma, and more.
The new funding supports clinical trials as well as preclinical work to identify biomarkers of therapeutic response.
Using a new mathematical model, researchers uncovered mutational signatures related to homologous recombination deficiency in up to one-fifth of breast cancers.
New data from Peregrine Pharmaceuticals, along with other recent research, suggests that surface proteins can be used to isolate cancer-specific exosomes to detect the presence of a tumor.
Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.
US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.
A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.
In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.